STERIS Irish FinCo Unlimited Company, STERIS plc’s wholly-owned subsidiary, priced $1.5 billion of senior notes: $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. Proceeds will help fund the pending Xodus Medical, Inc. acquisition.
STE · STERIS plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
STERIS plc and certain subsidiaries registered a shelf for debt securities, guarantees, ordinary and preferred shares, warrants, and units, to be sold in future offerings. Net proceeds are expected for general corporate purposes, with final terms set in prospectus supplements.
STERIS reported second-quarter adjusted earnings per diluted share of $2.94, up 19% from $2.47, helped by about $20 million of tariff refunds. The company raised its fiscal 2027 adjusted EPS outlook to $11.35 to $11.55 from $11.10 to $11.30, and said the outlook excludes the pending Exodus Medical acquisition.
STERIS agreed to acquire Xodus Medical for approximately $2.1 billion in cash at closing, plus potential earnout consideration of up to $150.0 million, and expects to close by December 31, 2026.
On November 4, 2026, STERIS plc entered a $1,600 million revolving credit facility, replacing the October 7, 2024 agreement, and arranged up to $500 million of delayed-draw term financing contingent on the Xodus Medical, Inc. acquisition closing.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY27 earnings call · Nov 5, 2026TL;DR. Adjusted EPS rose 19% to $2.94 and the fiscal 2027 adjusted EPS outlook was raised to $11.35 to $11.55, with Life Sciences growth outlook raised to 9% to 10%. Healthcare EBIT margin fell 110 basis points, while six-month free cash flow declined to $492.5 million.
- + Second-quarter total revenue rose 9% to $1.6 billion. new
- + Adjusted EPS rose 19% to $2.94 in the second quarter.
- + Life Sciences constant currency organic growth outlook raised to 9% to 10% from 6% to 7%. new
- + Fiscal 2027 adjusted EPS outlook raised to $11.35 to $11.55 from $11.10 to $11.30. new
- + Recently announced agreement to acquire Exodus Medical, a surgical specialties products business. new
- + Life Sciences segment margin reached a record 44.4%, up about 310 basis points. new
- − Underlying margins were down slightly; the quarter's margin gain was driven mainly by approximately $20 million of tariff refunds. new
- − Healthcare EBIT margin fell 110 basis points to 24%. new
- − AST segment margin fell about 60 basis points to 44.7%. new
- − Six-month free cash flow declined to $492.5 million from $527.7 million. new
- − Life Sciences backlog was $93 million at quarter end, down from the prior year. new
- − AST constant currency organic growth outlook lowered to 6% to 7% from 7% to 8%. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AST segment operating margin | 48% | the first three months of fiscal 2027 filing | — |
|
|
|||
| Capital expenditures | $87.5M | the first three months of fiscal 2027 filing | — |
| Debt-to-total capital ratio | 20.9% | the three months ended June 30, 2026 filing | — |
| Healthcare segment operating margin | 24.8% | the first three months of fiscal 2027 filing | — |
|
|
|||
| Life Sciences segment operating margin | 42.1% | the first three months of fiscal 2027 filing | — |
|
|
|||
| Adjusted Income from Operations non-GAAP | $354.8M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Income from Operations 285.8M
+65.3M Amortization of acquired intangible assets
+1.5M Acquisition and integration related charges
+0.3M Tax restructuring costs
+1.8M Amortization of inventory and property "step up" to fair value
+0M Restructuring charges
= Adjusted Income from Operations 354.8M
|
|||
| Adjusted Income Tax Rate non-GAAP | 25.9% | Three Months Ended June 30, 2026 | — |
| Adjusted Income, net of income tax non-GAAP | $254.3M | Three Months Ended June 30, 2026 | — |
| AST Constant Currency Organic Growth non-GAAP | 4.7% | Three Months Ended June 30, 2026 | — |
| AST Organic Growth non-GAAP | 5.8% | Three Months Ended June 30, 2026 | — |
| AST Segment Operating Income | $142.9M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Constant Currency Organic Growth non-GAAP | 6.2% | Three Months Ended June 30, 2026 | — |
| Constant currency organic revenue growth non-GAAP | 6% | first quarter of fiscal 2027 | — |
| Corporate Operating Loss | -$110.1M | Three Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | $279.6M | first quarter of fiscal 2027 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Cash flows from operating activities 367.1M
-87.5M Purchases of property, plant, equipment, and intangibles, net
+0M Proceeds from the sale of property, plant, equipment, and intangibles
= Free Cash Flow 279.6M
|
|||
| Healthcare Backlog | $444M | Three Months Ended June 30, 2026 | — |
| Healthcare Constant Currency Organic Growth non-GAAP | 6.4% | Three Months Ended June 30, 2026 | — |
| Healthcare Segment Operating Income | $260.2M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Life Sciences Backlog | $109.9M | Three Months Ended June 30, 2026 | — |
| Life Sciences Constant Currency Organic Growth non-GAAP | 7.9% | Three Months Ended June 30, 2026 | — |
| Life Sciences Organic Growth non-GAAP | 8.6% | Three Months Ended June 30, 2026 | — |
| Life Sciences Segment Operating Income | $61.8M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Organic Growth non-GAAP | 6.8% | Three Months Ended June 30, 2026 | — |
| Total Backlog | $553.9M | Three Months Ended June 30, 2026 | — |
| U.S. GAAP Growth | 7.3% | Three Months Ended June 30, 2026 | — |
| Employee turnover rate | 13% | fiscal 2026 filing | — |
| Lost-time Incident Rate | 0.32 | Fiscal 2026 filing | — |
| Ordinary shares repurchased | 0.9M | fiscal 2026 filing | — |
| Total constant currency organic growth non-GAAP | 7.3% | fiscal 2026 filing | — |
| Total employees | 17,937 | Fiscal 2026 filing | — |
| Total income from operations before adjustments (AST) | $524.7M | Year Ended March 31, 2026 filing | — |
| Total income from operations before adjustments (Healthcare) | $1.04B | Year Ended March 31, 2026 filing | — |
| Total income from operations before adjustments (Life Sciences) | $251M | Year Ended March 31, 2026 filing | — |
| Total organic growth non-GAAP | 8.7% | fiscal 2026 filing | — |
| Total Recordable Incident Rate | 1.03 | Fiscal 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STE
this stock
STERIS plc
|
$25.00B | +1.5% | +8.7% | 32.5 | 2.2% |
|
ABT
Abbott Laboratories
|
$181.35B | -16.4% | +5.7% | 39.1 | 1.1% |
|
MDT
Medtronic plc
|
$130.88B | +6.5% | +8.4% | 25.2 | 1.8% |
|
SYK
Stryker Corp
|
$120.88B | -9.7% | +11.2% | 33.8 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.37B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 20
STERIS Irish FinCo Unlimited Company, STERIS plc’s wholly-owned subsidiary, priced $1.5 billion of senior notes: $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. Proceeds will help fund the pending Xodus Medical, Inc. acquisition.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STE | +0.1% | +14.3% | +19.5% | +13.3% | +1.5% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +2.4% | +19.1% | +22.4% | +16.4% | -5.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.